These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27770217)

  • 1. Partial Adenosine A1 Agonist in Heart Failure.
    Dinh W; Albrecht-Küpper B; Gheorghiade M; Voors AA; van der Laan M; Sabbah HN
    Handb Exp Pharmacol; 2017; 243():177-203. PubMed ID: 27770217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial.
    Voors AA; Bax JJ; Hernandez AF; Wirtz AB; Pap AF; Ferreira AC; Senni M; van der Laan M; Butler J;
    Eur J Heart Fail; 2019 Nov; 21(11):1426-1433. PubMed ID: 31523892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A
    Meibom D; Albrecht-Küpper B; Diedrichs N; Hübsch W; Kast R; Krämer T; Krenz U; Lerchen HG; Mittendorf J; Nell PG; Süssmeier F; Vakalopoulos A; Zimmermann K
    ChemMedChem; 2017 May; 12(10):728-737. PubMed ID: 28488817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capadenoson, a clinically trialed partial adenosine A
    Baltos JA; Vecchio EA; Harris MA; Qin CX; Ritchie RH; Christopoulos A; White PJ; May LT
    Biochem Pharmacol; 2017 Jul; 135():79-89. PubMed ID: 28344125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure.
    Voors AA; Düngen HD; Senni M; Nodari S; Agostoni P; Ponikowski P; Bax JJ; Butler J; Kim RJ; Dorhout B; Dinh W; Gheorghiade M
    J Clin Pharmacol; 2017 Apr; 57(4):440-451. PubMed ID: 27624622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction.
    Voors AA; Shah SJ; Bax JJ; Butler J; Gheorghiade M; Hernandez AF; Kitzman DW; McMurray JJV; Wirtz AB; Lanius V; van der Laan M; Solomon SD
    Eur J Heart Fail; 2018 Nov; 20(11):1601-1610. PubMed ID: 30225882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CVT-510: a selective A1 adenosine receptor agonist.
    Cheung JW; Lerman BB
    Cardiovasc Drug Rev; 2003; 21(4):277-92. PubMed ID: 14647532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure.
    Greene SJ; Sabbah HN; Butler J; Voors AA; Albrecht-Küpper BE; Düngen HD; Dinh W; Gheorghiade M
    Heart Fail Rev; 2016 Jan; 21(1):95-102. PubMed ID: 26701329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure.
    Sabbah HN; Gupta RC; Kohli S; Wang M; Rastogi S; Zhang K; Zimmermann K; Diedrichs N; Albrecht-Küpper BE
    Circ Heart Fail; 2013 May; 6(3):563-71. PubMed ID: 23564604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of two selective A
    Cooper SL; March J; Sabbatini AR; Hill SJ; Jörg M; Scammells PJ; Woolard J
    Br J Pharmacol; 2020 Jan; 177(2):346-359. PubMed ID: 31596949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I
    Long VP; Bonilla IM; Baine S; Glynn P; Kumar S; Schober K; Mowrey K; Weiss R; Lee NY; Mohler PJ; Györke S; Hund TJ; Fedorov VV; Carnes CA
    Life Sci; 2020 Jan; 240():117068. PubMed ID: 31751583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tecadenoson: a novel, selective A1 adenosine receptor agonist.
    Peterman C; Sanoski CA
    Cardiol Rev; 2005; 13(6):315-21. PubMed ID: 16230891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Partial AdeNosine A1 receptor agonist in patients with Chronic Heart failure and preserved Ejection fraction (PANACHE) trial.
    Bertero E; Maack C
    Cardiovasc Res; 2019 Jul; 115(8):e71-e73. PubMed ID: 31180465
    [No Abstract]   [Full Text] [Related]  

  • 14. INO-8875, a highly selective A1 adenosine receptor agonist: evaluation of chronotropic, dromotropic, and hemodynamic effects in rats.
    Mor M; Shalev A; Dror S; Pikovsky O; Beharier O; Moran A; Katz A; Etzion Y
    J Pharmacol Exp Ther; 2013 Jan; 344(1):59-67. PubMed ID: 23055540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure.
    Rueda P; Merlin J; Chimenti S; Feletou M; Paysant J; White PJ; Christopoulos A; Sexton PM; Summers RJ; Charman WN; May LT; Langmead CJ
    Front Pharmacol; 2021; 12():628060. PubMed ID: 33776771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial adenosine A1 receptor agonists for cardiovascular therapies.
    Albrecht-Küpper BE; Leineweber K; Nell PG
    Purinergic Signal; 2012 Feb; 8(Suppl 1):91-9. PubMed ID: 22081230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Effect of Adenosine A1 Receptor Activation on Renal O2 Consumption.
    Babich V; Vadnagara K; Di Sole F
    J Cell Physiol; 2015 Dec; 230(12):3093-104. PubMed ID: 26010290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A1 adenosine receptor agonists and their potential therapeutic applications.
    Elzein E; Zablocki J
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1901-10. PubMed ID: 19012505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Positive Allosteric Modulator of the Adenosine A1 Receptor Selectively Inhibits Primary Afferent Synaptic Transmission in a Neuropathic Pain Model.
    Imlach WL; Bhola RF; May LT; Christopoulos A; Christie MJ
    Mol Pharmacol; 2015 Sep; 88(3):460-8. PubMed ID: 26104547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotection induced by adenosine A1 receptor agonists in a cardiac cell ischemia model involves cooperative activation of adenosine A2A and A2B receptors by endogenous adenosine.
    Urmaliya VB; Church JE; Coupar IM; Rose'Meyer RB; Pouton CW; White PJ
    J Cardiovasc Pharmacol; 2009 May; 53(5):424-33. PubMed ID: 19333129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.